Mbx Biosciences Inc (MBX) Institutional Investor Snapshot (176 Funds, Q2 2026)

MBX ranks #3321 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

MBX is a top-conviction position for NVP Associates, LLC — at 35.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in MBX belongs to Frazier Life Sciences Management, L.P., but the position matters far more to NVP Associates, LLC, who has 35.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its MBX position for two straight quarters, increasing it by $293.3M to reach $293.8M today.

EcoR1 Capital, LLC has trimmed its MBX position for two straight quarters, cutting it by $45.5M while still holding $21.4M.

MBX is down 1.1% today, but institutions show net buying of $311.0M this quarter — a divergence between today's price move and the underlying institutional flow.

MBX reported a net loss of $87.0M in its latest fiscal year.

• Not yet profitable — net loss of $87.0M in the latest fiscal year
• Net income declined year over year, from -$61.9M to -$87.0M
• Operating cash flow was negative, using $79.9M in cash
• Current ratio of 24.62x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.04x equity — within a conventional range